From the validation set (n = 190), 15.3% (n = 29) of NSCLC patients had EGFR mutation (exon 19 deletions or exon 21 mutation), 13.7% (n = 26) were KRAS mutated, 4.2% (n = 8) had EML4-ALK fusion, 2.6% (n = 5) had BRAF V600E mutation. Here, ALK is linked to non-small cell lung carcinoma.